Bullous pemphigoid receiving a novel long‐acting dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor omarigliptin in a patient with type 2 diabetes: A case report

Guardado en:

Detalles Bibliográficos
Autores principales:	Hiroshi Kasamatsu, Takenao Chino, Noritaka Oyama, Takakiyo Nakaya, Minoru Hasegawa
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	anti‐BP180‐NC16a autoantibody autoimmune bullous disease bullous pemphigoid dipeptidyl‐peptidase‐4 inhibitor omarigliptin Dermatology RL1-803 Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/12a7ff4d63894838ad4218439e34b9af
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:12a7ff4d63894838ad4218439e34b9af
record_format	dspace
spelling	oai:doaj.org-article:12a7ff4d63894838ad4218439e34b9af2021-11-10T05:50:45ZBullous pemphigoid receiving a novel long‐acting dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor omarigliptin in a patient with type 2 diabetes: A case report2574-459310.1002/cia2.12162https://doaj.org/article/12a7ff4d63894838ad4218439e34b9af2021-08-01T00:00:00Zhttps://doi.org/10.1002/cia2.12162https://doaj.org/toc/2574-4593Hiroshi KasamatsuTakenao ChinoNoritaka OyamaTakakiyo NakayaMinoru HasegawaWileyarticleanti‐BP180‐NC16a autoantibodyautoimmune bullous diseasebullous pemphigoiddipeptidyl‐peptidase‐4 inhibitoromarigliptinDermatologyRL1-803Immunologic diseases. AllergyRC581-607ENJournal of Cutaneous Immunology and Allergy, Vol 4, Iss 4, Pp 89-91 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	anti‐BP180‐NC16a autoantibody autoimmune bullous disease bullous pemphigoid dipeptidyl‐peptidase‐4 inhibitor omarigliptin Dermatology RL1-803 Immunologic diseases. Allergy RC581-607
spellingShingle	anti‐BP180‐NC16a autoantibody autoimmune bullous disease bullous pemphigoid dipeptidyl‐peptidase‐4 inhibitor omarigliptin Dermatology RL1-803 Immunologic diseases. Allergy RC581-607 Hiroshi Kasamatsu Takenao Chino Noritaka Oyama Takakiyo Nakaya Minoru Hasegawa Bullous pemphigoid receiving a novel long‐acting dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor omarigliptin in a patient with type 2 diabetes: A case report
format	article
author	Hiroshi Kasamatsu Takenao Chino Noritaka Oyama Takakiyo Nakaya Minoru Hasegawa
author_facet	Hiroshi Kasamatsu Takenao Chino Noritaka Oyama Takakiyo Nakaya Minoru Hasegawa
author_sort	Hiroshi Kasamatsu
title	Bullous pemphigoid receiving a novel long‐acting dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor omarigliptin in a patient with type 2 diabetes: A case report
title_short	Bullous pemphigoid receiving a novel long‐acting dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor omarigliptin in a patient with type 2 diabetes: A case report
title_full	Bullous pemphigoid receiving a novel long‐acting dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor omarigliptin in a patient with type 2 diabetes: A case report
title_fullStr	Bullous pemphigoid receiving a novel long‐acting dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor omarigliptin in a patient with type 2 diabetes: A case report
title_full_unstemmed	Bullous pemphigoid receiving a novel long‐acting dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor omarigliptin in a patient with type 2 diabetes: A case report
title_sort	bullous pemphigoid receiving a novel long‐acting dipeptidyl‐peptidase‐4 (dpp‐4) inhibitor omarigliptin in a patient with type 2 diabetes: a case report
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/12a7ff4d63894838ad4218439e34b9af
work_keys_str_mv	AT hiroshikasamatsu bullouspemphigoidreceivinganovellongactingdipeptidylpeptidase4dpp4inhibitoromarigliptininapatientwithtype2diabetesacasereport AT takenaochino bullouspemphigoidreceivinganovellongactingdipeptidylpeptidase4dpp4inhibitoromarigliptininapatientwithtype2diabetesacasereport AT noritakaoyama bullouspemphigoidreceivinganovellongactingdipeptidylpeptidase4dpp4inhibitoromarigliptininapatientwithtype2diabetesacasereport AT takakiyonakaya bullouspemphigoidreceivinganovellongactingdipeptidylpeptidase4dpp4inhibitoromarigliptininapatientwithtype2diabetesacasereport AT minoruhasegawa bullouspemphigoidreceivinganovellongactingdipeptidylpeptidase4dpp4inhibitoromarigliptininapatientwithtype2diabetesacasereport
_version_	1718440532195147776

Bullous pemphigoid receiving a novel long‐acting dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor omarigliptin in a patient with type 2 diabetes: A case report

Ejemplares similares